Some health care workers who call themselves "Lyme literate" insist that chronic Lyme disease is frequently diagnosed and treated by primary care physicians. Others, however, including the American Academy of Pediatrics and the Infectious Diseases Society of America, state that there is no convincing biological evidence that chronic Lyme disease exists.
Many doctors are concerned with the potential dangers associated with the prolonged and intensive use of oral and intravenous antibiotics (the recommended treatment for chronic Lyme disease), such as blood clots and life threatening infections. A study soon to be published in The Journal of Pediatrics attempts to determine how often chronic Lyme disease is actually being diagnosed and treated.
Named for a community in Connecticut where it was first diagnosed, Lyme disease is a multi-system infection caused by the bacteria B. burgdoferi. Treatment typically includes a 10-28 day course of oral antibiotics. "Lyme literate" groups, such as the International Lyme and Associated Diseases Society (ILADS), define chronic Lyme disease as a debilitating illness caused by a persistent infection of B. burgdoferi; symptoms include fatigue, difficulty concentrating, headaches, and irritability. Treatment requires oral and/or intravenous antibiotic therapy that can last from several months to several years.
Dr. Michael Johnson, now at the Hospital of Saint Raphael in New Haven, and Dr. Henry Feder, of the University of Connecticut Health Center, attempted to determine how frequently Connecticut doctors were diagnosing and treating chronic Lyme disease. Of the 285 primary care physicians who responded to the survey, nearly one-half did not believe that chronic Lyme disease is a legitimate diagnosis, and 48% were undecided. Only 6 physicians—or 2.1%—diagnosed and treated patients for chronic Lyme disease. These 6 physicians treated patients for an average of 20 weeks with oral antibiotics; however, because these six physicians did not treat their patients with months to years of oral and/or intravenous antibiotics, they do not fit into the "Lyme literate" category.
Contrary to the assertions of the "Lyme literate" community, Dr. Feder does not believe intravenous antibiotic treatment is common practice. "The 6 physicians in our study who treated patients with chronic Lyme disease do not fit into the 'Lyme literate' group," he explains, "because they treated their patients for an average of 20 weeks—not months to years—and it does not appear that intravenous therapy was used." According to Dr. Feder, "Physicians who diagnose patients with chronic Lyme disease, and put these patients in harm's way with months to years of potentially dangerous antibiotics, are outliers." These findings call into question the claims of "Lyme literate" advocacy groups, like ILADS, that chronic Lyme disease is frequently diagnosed and treated by many primary care physicians.
Although the number of physicians diagnosing and treating patients with chronic Lyme disease may be small, their influence seems to be growing. "The 'Lyme literate' network has been pivotal in advocating legislation in multiple states requiring insurance companies to cover the costs of intravenous therapy for presumed chronic Lyme disease," Dr. Feder notes. The debate over chronic Lyme disease is likely to continue as insurance companies and legislative bodies become more involved.
The study, reported in "Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians" by Michael Johnson, MD and Henry Feder, Jr. MD, appears in The Journal of Pediatrics, DOI 10.1016/j.jpeds.2010.06.031, published by Elsevier.
Brigid Huey | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences